종양학 임상시험 시장 규모, 점유율, 성장 및 세계 산업 분석 : 유형별, 용도별, 지역별 인사이트와 예측(2026-2034년)

Growth Factors of oncology clinical trials Market

The global oncology clinical trials market is experiencing significant growth due to the rising prevalence of cancer, increasing focus on precision medicine, and the growing outsourcing of clinical trial procedures. According to Fortune Business Insights, the market was valued at USD 18.97 billion in 2025, is projected to reach USD 20.55 billion in 2026, and is expected to expand to USD 40.49 billion by 2034, exhibiting a CAGR of 8.85% during 2026-2034. North America dominated the market in 2025 with a 42.52% share, attributed to the high concentration of contract research organizations (CROs), robust infrastructure for precision medicine, and active clinical trial outsourcing by pharmaceutical firms.

Oncology clinical trials are research studies evaluating the safety and efficacy of novel therapeutics, diagnostics, and medical devices. The growing global burden of cancer has driven pharmaceutical companies to conduct an increasing number of trials. For instance, in August 2024, OncoSure Testing launched a rapid cancer screening test to improve early detection accessibility, reflecting the industry's focus on innovation.

Market Dynamics

Market Drivers:

The rising prevalence of cancer and increasing number of clinical trials are the primary growth drivers. According to WHO 2022 data, there were approximately 20 million new cancer cases and 9.7 million cancer-related deaths, highlighting the urgent need for novel diagnostics and therapeutics. Around 5,306 clinical trials for malignant neoplasms were registered in 2024, showing a growth of 16.7% from 2010, emphasizing the increasing research focus.

Market Restraints:

Stringent regulatory scenarios and insufficient funding restrict market growth. Lengthy approval processes can delay patient recruitment and trial conduct, particularly in developing regions like Brazil, where regulatory complexity and limited clinical understanding impede timely trial execution.

Opportunities:

The growing focus on novel therapeutics by pharmaceutical and research institutes provides substantial market opportunities. For example, Shandong Suncadia Medicine Co., Ltd. initiated a Phase II trial of HRS-7058 in April 2025 for advanced malignant tumors, expected to complete in October 2027. Similarly, LaNova Medicines Limited launched a Phase II study in October 2024 for LM-299 in solid tumors, projected to complete in July 2027.

Challenges:

High costs in developed countries, patient recruitment difficulties, and retention issues constrain the efficient execution of trials. Oncology trials often require longer durations, complex protocols, and specialized infrastructure, making them cost-intensive. Misconceptions and lack of awareness among potential participants further limit enrollment rates.

Market Trends

• Decentralized Clinical Trials (DCTs): Increasing use of telemedicine, wearable devices, and at-home diagnostics improves patient participation in rural and underserved areas.
• Artificial Intelligence (AI) and Big Data: AI assists in patient cohort identification, trial outcome prediction, and monitoring, while Big Data supports adaptive trial designs.
• Regulatory Fast-Track Initiatives: FDA and EMA fast-track, orphan drug, and breakthrough therapy designations accelerate oncology trial approvals and investment appeal.

Segmentation Analysis

By Phase:

• Phase III dominated in 2024 due to the higher number and longer duration of trials, with 418 Phase III trials registered for malignant neoplasms in 2024, reflecting a 114.4% growth since 2000.
• Phase II is expected to grow at the fastest CAGR, supported by small and mid-sized pharmaceutical companies outsourcing trials to CROs.

By Type:

• Breast cancer trials held the largest share in 2024, reflecting strong pharmaceutical R&D focus.
• Prostate cancer trials are projected to grow at the fastest rate due to increasing disease prevalence and the need for effective diagnostics and therapeutics.

Regional Outlook

North America: Market value USD 8.06 billion in 2025, leading globally due to the presence of major CROs (IQVIA, ICON, Thermo Fisher) and adoption of precision medicine trials. The U.S. remains a key contributor.

Europe: Growth is driven by R&D investments, such as AstraZeneca's USD 808.5 billion commitment in 2024 for pharmaceutical development in the U.K.

Asia Pacific: Projected to grow at the fastest CAGR, fueled by government funding, increasing cancer burden, and the development of personalized medicine and devices.

Rest of the World: Latin America and Middle East & Africa are attractive for cost-effective clinical trials, benefiting from less complex regulatory requirements.

Competitive Landscape

The global market is consolidated, with key players such as IQVIA Inc., ICON plc, Charles River Laboratories, Parexel International, Thermo Fisher Scientific, Medpace, Fortrea, and Syneos Health. Companies focus on partnerships, service expansion, and development of novel therapeutics. Notable developments include Thermo Fisher's collaboration with the NCI in July 2024 for the myeloMATCH precision medicine trial and Parexel's partnerships in Japan and China to accelerate oncology clinical research.

Conclusion

The oncology clinical trials market is projected to grow from USD 18.97 billion in 2025 to USD 40.49 billion by 2034, driven by the increasing cancer burden, outsourcing of clinical trials, rising adoption of AI and Big Data, and growing pharmaceutical focus on novel therapeutics. North America leads globally, followed by Europe and Asia Pacific. The expansion of decentralized trials, regulatory fast-track initiatives, and innovative trial designs are expected to enhance patient participation, accelerate clinical research, and strengthen oncology drug development throughout the forecast period.

Segmentation By Phase

• Phase I
• Phase II
• Phase III
• Phase IV

By Type

• Breast Cancer
• Melanoma
• Colorectal Cancer
• Prostate Cancer
• Lung Cancer
• Others

By Region

• North America (By Phase, Type, and Country)
  • U.S.
  • Canada
• Europe (By Phase, Type, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Phase, Type, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Rest of the World (By Phase and Type)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Number of Oncology Clinical Trials - by Key Countries, 2025
• 4.2. Distribution of Oncology Clinical Trials
• 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)

5. Global Oncology Clinical Trials Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Phase
  • 5.1.1. Phase I
  • 5.1.2. Phase II
  • 5.1.3. Phase III
  • 5.1.4. Phase IV
• 5.2. Market Analysis, Insights and Forecast - By Types
  • 5.2.1. Breast Cancer
  • 5.2.2. Melanoma
  • 5.2.3. Colorectal Cancer
  • 5.2.4. Prostate Cancer
  • 5.2.5. Lung Cancer
  • 5.2.6. Others
• 5.3. Market Analysis, Insights and Forecast - By Region
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. Asia Pacific
  • 5.3.4. Rest of the World

6. North America Oncology Clinical Trials Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Phase
  • 6.1.1. Phase I
  • 6.1.2. Phase II
  • 6.1.3. Phase III
  • 6.1.4. Phase IV
• 6.2. Market Analysis, Insights and Forecast - By Types
  • 6.2.1. Breast Cancer
  • 6.2.2. Melanoma
  • 6.2.3. Colorectal Cancer
  • 6.2.4. Prostate Cancer
  • 6.2.5. Lung Cancer
  • 6.2.6. Others
• 6.3. Market Analysis, Insights and Forecast - By Country
  • 6.3.1. U.S.
  • 6.3.2. Canada

7. Europe Oncology Clinical Trials Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Phase
  • 7.1.1. Phase I
  • 7.1.2. Phase II
  • 7.1.3. Phase III
  • 7.1.4. Phase IV
• 7.2. Market Analysis, Insights and Forecast - By Types
  • 7.2.1. Breast Cancer
  • 7.2.2. Melanoma
  • 7.2.3. Colorectal Cancer
  • 7.2.4. Prostate Cancer
  • 7.2.5. Lung Cancer
  • 7.2.6. Others
• 7.3. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.3.1. U.K.
  • 7.3.2. Germany
  • 7.3.3. France
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Scandinavia
  • 7.3.7. Rest of the Europe

8. Asia Pacific Oncology Clinical Trials Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Phase
  • 8.1.1. Phase I
  • 8.1.2. Phase II
  • 8.1.3. Phase III
  • 8.1.4. Phase IV
• 8.2. Market Analysis, Insights and Forecast - By Types
  • 8.2.1. Breast Cancer
  • 8.2.2. Melanoma
  • 8.2.3. Colorectal Cancer
  • 8.2.4. Prostate Cancer
  • 8.2.5. Lung Cancer
  • 8.2.6. Others
• 8.3. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.3.1. Japan
  • 8.3.2. China
  • 8.3.3. India
  • 8.3.4. Australia
  • 8.3.5. Southeast Asia
  • 8.3.6. Rest of Asia Pacific

9. Rest of the World Oncology Clinical Trials Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Phase
  • 9.1.1. Phase I
  • 9.1.2. Phase II
  • 9.1.3. Phase III
  • 9.1.4. Phase IV
• 9.2. Market Analysis, Insights and Forecast - By Types
  • 9.2.1. Breast Cancer
  • 9.2.2. Melanoma
  • 9.2.3. Colorectal Cancer
  • 9.2.4. Prostate Cancer
  • 9.2.5. Lung Cancer
  • 9.2.6. Others

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2025)
• 10.2. Company Profiles
  • 10.2.1. IQVIA Inc.
    • 10.2.1.1. Overview
    • 10.2.1.2. Products
    • 10.2.1.3. SWOT Analysis
    • 10.2.1.4. Recent Developments
    • 10.2.1.5. Strategies
    • 10.2.1.6. Financials (Based on Availability)
  • 10.2.2. Thermo Fisher Scientific Inc.
    • 10.2.2.1. Overview
    • 10.2.2.2. Products
    • 10.2.2.3. SWOT Analysis
    • 10.2.2.4. Recent Developments
    • 10.2.2.5. Strategies
    • 10.2.2.6. Financials (Based on Availability)
  • 10.2.3. Parexel International Corporation
    • 10.2.3.1. Overview
    • 10.2.3.2. Products
    • 10.2.3.3. SWOT Analysis
    • 10.2.3.4. Recent Developments
    • 10.2.3.5. Strategies
    • 10.2.3.6. Financials (Based on Availability)
  • 10.2.4. Medpace
    • 10.2.4.1. Overview
    • 10.2.4.2. Products
    • 10.2.4.3. SWOT Analysis
    • 10.2.4.4. Recent Developments
    • 10.2.4.5. Strategies
    • 10.2.4.6. Financials (Based on Availability)
  • 10.2.5. ICON plc
    • 10.2.5.1. Overview
    • 10.2.5.2. Products
    • 10.2.5.3. SWOT Analysis
    • 10.2.5.4. Recent Developments
    • 10.2.5.5. Strategies
    • 10.2.5.6. Financials (Based on Availability)
  • 10.2.6. Charles River Laboratories
    • 10.2.6.1. Overview
    • 10.2.6.2. Products
    • 10.2.6.3. SWOT Analysis
    • 10.2.6.4. Recent Developments
    • 10.2.6.5. Strategies
    • 10.2.6.6. Financials (Based on Availability)
  • 10.2.7. Fortrea
    • 10.2.7.1. Overview
    • 10.2.7.2. Products
    • 10.2.7.3. SWOT Analysis
    • 10.2.7.4. Recent Developments
    • 10.2.7.5. Strategies
    • 10.2.7.6. Financials (Based on Availability)
  • 10.2.8. Syneos Health
    • 10.2.8.1. Overview
    • 10.2.8.2. Products
    • 10.2.8.3. SWOT Analysis
    • 10.2.8.4. Recent Developments
    • 10.2.8.5. Strategies
    • 10.2.8.6. Financials (Based on Availability)